Use of human immunodeficiency virus (HIV) type 1 and 2 recombinant strip immunoblot assay to resolve enzyme immunoassay anti-HIV-2-repeatably reactive samples after anti-HIV-1/2 combination enzyme immunoassay screening.
With the implementation of combination human immunodeficiency virus types 1 and 2 (HIV-1/2) antibody enzyme immunoassay (EIA) in donor screening in 1992, the supplemental testing algorithm changed to require the use of a Food and Drug Administration (FDA)-licensed HIV-1 Western blot (WB) or immunofluorescence assay, as well as an FDA-licensed HIV-2 EIA. When HIV-2 EIA-reactive specimens are identified, further testing to confirm HIV-2 infection is recommended. Currently, a licensed HIV-2 supplemental assay is not available. The sensitivity of an HIV-1/2 recombinant strip immunoblot assay (SIA) for HIV-2 was determined on the basis of the analysis of 65 HIV-2-positive samples identified by the Centers for Disease Control and Prevention (CDC). Anti-HIV-1/2 combination EIA-repeatably reactive (RR) specimens from seven blood centers and their affiliated hospitals were tested in parallel by HIV-1 WB and HIV-2 EIA. Anti-HIV-2 EIA-RR specimens were further tested by HIV-1/2 SIA. Specimens interpreted as positive for HIV-2 or HIV-1/2 were referred to the CDC for final resolution of antibody status. Ninety-seven percent (63/65) of known HIV-2-positive samples tested positive for HIV-2 only or HIV-1/2 on the HIV-1/2 SIA. A total of 1048 anti-HIV-1/2 combination-EIA-RR specimens were evaluated. Sixty-nine percent (75/109) of the WB-positive specimens were HIV-2 EIA-RR, while only 9 percent (84/939) of WB-indeterminate or WB-negative specimens tested HIV-2 EIA-RR. The HIV-1/2 SIA resolved 91 percent of HIV-2 EIA-RR samples as negative. Four HIV-2 EIA-RR specimens (all HIV-1 WB-positive) were classified as positive for HIV-1 and HIV-2 in the HIV-1/2 SIA. Final interpretation of these specimens by CDC was that they were reactive for HIV-1 with cross-reactivity to HIV-2. No confirmed HIV-2-positive specimens were detected. The HIV-1/2 SIA is currently useful for resolving HIV-2 EIA-RR specimens.